newsfilter
← Latest News
GlobeNewswire·

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of